Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 11, 2020Journal of Medical EconomicsOpen Access

Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJohn MascarenhasMMManeesha MehraJHJianming He

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mascarenhas et al. (2020) studied this question.

synapsesocial.com/papers/69dff21c2c052bbf722554bahttps://doi.org/10.1080/13696998.2020.1741381
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.2002 · 1,724 citations
  2. 2Improved Estimates of Cancer-Specific Survival Rates From Population-Based Data2010 · 456 citations
  3. 3A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis2012 · 2,108 citations
  4. 4Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation2017 · 220 citations
  5. 5Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib2015 · 27 citations